Olaf Stuve
Neurology · Dallas, TXNPI 1760442420
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,362 of the $63,286 with a category attached, or 74.8%. 7 manufacturers reported payments, led by Novartis at 34.0% of the total. Reporting peaked in 2019 at $19,495 and has fallen 54.9% since, to $8,785 in 2024. Among neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 36 payments — averaging $1757.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$22K
- EMD Serono, Inc.$18K
- Genentech USA, Inc.$10K
- Merck Kgaa$7K
- Bristol Myers Squibb$5K
- TG Therapeutics, Inc.$2K
- plus $170 from 1 others
Across 9 payments — averaging $260,948 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$2M
- Sanofi$359K
- Novartis$7K
What the payments were for
- Consulting fees$47,36275%
- Speaking & faculty fees$8,41213%
- Travel & lodging$1,5182%
- Food & beverage$8681%
- Education$5,1278%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 8 | $21,509 |
| EMD Serono, Inc. | 15 | $18,024 |
| Genentech USA, Inc. | 4 | $9,717 |
| Merck Kgaa | 2 | $6,715 |
| Bristol Myers Squibb | 4 | $4,750 |
| TG Therapeutics, Inc. | 1 | $2,400 |
| Genentech, Inc. | 2 | $170 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAYZENT$10,380
- KESIMPTA$5,422
- Evobrutinib$4,999
- Ozanimod$4,750
- Non-Covered Product$4,718
- OCREVUS$2,895
- Enspryng$2,104
How this compares
$63,286 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.